(2 references)
Catalog No. ABIN3342339
Supplier Product No.: sr302557
$306.90
Plus shipping costs $50.00
1 kit
Shipping to:
United States
Delivery in 4 to 8 Business Days
Quick Overview for Human VEGFR2 siRNA Oligo (ABIN3342339)
Gene
VEGFR2/CD309 (VEGFR2)
(VEGF Receptor 2 (VEGFR2))
Species
Human
Application
RNA Interference (RNAi)
Purification
HPLC purified
-
-
Supplier Product No.
- sr302557
-
Supplier
- OriGene
-
Oligo-Type
- siRNA Oligo
-
Purpose
- siRNA (27 mer) kit with 3 gene-specific unique siRNA duplexes and negative control for gene knockdown.
-
Brand
- Trilencer-27
-
Sequence
- Available with shipment
-
Components
-
- KDR (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each
- Trilencer-27 Universal Scrambled Negative Control siRNA Duplex - 2 nmol
- RNAse free siRNA Duplex Resuspension Buffer - 2 ml
-
-
-
-
Application Notes
-
- No. of transfections: Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final conc. 10 nM)
- Quality Control: Tested by ESI-MS
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
-
- 2 nmoles of each duplex is provided (including the control duplex). Addition of 100 μL of RNase-free Duplex Buffer will result in 20 μM final concentration, vortex thoroughly and microfuge prior to use.
- Heat to 94 °C for 2 minutes, remove from heat and allow tube to cool to room temperature. The oligos were dried in duplex form so heating may not be necessary, however following this protocol ensures that the contents will be fully duplexed.
-
Storage
- -20 °C
-
Storage Comment
- The dried duplexes can be stored at 4 °C. However, once reconstituted with dH2O, the plasmids must be stored at -20°C.
-
Expiry Date
- 12 months
-
-
-
: "VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 20, Issue 14, pp. 3849-61, (2014) (PubMed).
: "Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy." in: Cancer research, Vol. 71, Issue 16, pp. 5512-21, (2011) (PubMed).
-
: "VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 20, Issue 14, pp. 3849-61, (2014) (PubMed).
-
- VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))
-
Alternative Name
- KDR
Target
-
You are here:
